Brief: Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data In Urinary Tract And Pulmonary Infection Indications With Bisphosphocin® Compounds
07/10/2026 13:06
BRIEF-Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data In Urinary Tract And Pulmonary Infection Indications With Bisphosphocin® Compounds Oct 7 (Reuters) - Lakewood-amedex Biotherapeutics Inc LABT.O:
LAKEWOOD-AMEDEX BIOTHERAPEUTICS ANNOUNCES POSITIVE PRECLINICAL DATA IN URINARY TRACT AND PULMONARY INFECTION INDICATIONS WITH BISPHOSPHOCIN® COMPOUNDS
LAKEWOOD-AMEDEX BIOTHERAPEUTICS - BISPHOSPHOCIN NU-3 PHASE 2A TRIAL TOPLINE DATA EXPECTED Q1 2027
Source text: ID:nPn3t7M1Ga
Further company coverage: LABT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lakewood-amedex Biotherapeutics
See all newsBrief: Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data In Urinary Tract And Pulmonary Infection Indications With Bisphosphocin® Compounds
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 08:29 PM